QQQ   444.01 (-0.18%)
AAPL   171.48 (-1.06%)
MSFT   420.72 (-0.17%)
META   485.58 (-1.68%)
GOOGL   150.93 (+0.04%)
AMZN   180.38 (+0.31%)
TSLA   175.79 (-2.25%)
NVDA   903.56 (+0.12%)
NIO   4.50 (-3.64%)
AMD   180.49 (+0.50%)
BABA   72.36 (+1.08%)
T   17.60 (+0.28%)
F   13.28 (+1.68%)
MU   117.89 (-1.14%)
CGC   8.63 (-9.63%)
GE   175.53 (-2.55%)
DIS   122.36 (+1.14%)
AMC   3.72 (-14.29%)
PFE   27.75 (-0.11%)
PYPL   66.99 (+0.63%)
XOM   116.24 (+1.10%)
QQQ   444.01 (-0.18%)
AAPL   171.48 (-1.06%)
MSFT   420.72 (-0.17%)
META   485.58 (-1.68%)
GOOGL   150.93 (+0.04%)
AMZN   180.38 (+0.31%)
TSLA   175.79 (-2.25%)
NVDA   903.56 (+0.12%)
NIO   4.50 (-3.64%)
AMD   180.49 (+0.50%)
BABA   72.36 (+1.08%)
T   17.60 (+0.28%)
F   13.28 (+1.68%)
MU   117.89 (-1.14%)
CGC   8.63 (-9.63%)
GE   175.53 (-2.55%)
DIS   122.36 (+1.14%)
AMC   3.72 (-14.29%)
PFE   27.75 (-0.11%)
PYPL   66.99 (+0.63%)
XOM   116.24 (+1.10%)
QQQ   444.01 (-0.18%)
AAPL   171.48 (-1.06%)
MSFT   420.72 (-0.17%)
META   485.58 (-1.68%)
GOOGL   150.93 (+0.04%)
AMZN   180.38 (+0.31%)
TSLA   175.79 (-2.25%)
NVDA   903.56 (+0.12%)
NIO   4.50 (-3.64%)
AMD   180.49 (+0.50%)
BABA   72.36 (+1.08%)
T   17.60 (+0.28%)
F   13.28 (+1.68%)
MU   117.89 (-1.14%)
CGC   8.63 (-9.63%)
GE   175.53 (-2.55%)
DIS   122.36 (+1.14%)
AMC   3.72 (-14.29%)
PFE   27.75 (-0.11%)
PYPL   66.99 (+0.63%)
XOM   116.24 (+1.10%)
QQQ   444.01 (-0.18%)
AAPL   171.48 (-1.06%)
MSFT   420.72 (-0.17%)
META   485.58 (-1.68%)
GOOGL   150.93 (+0.04%)
AMZN   180.38 (+0.31%)
TSLA   175.79 (-2.25%)
NVDA   903.56 (+0.12%)
NIO   4.50 (-3.64%)
AMD   180.49 (+0.50%)
BABA   72.36 (+1.08%)
T   17.60 (+0.28%)
F   13.28 (+1.68%)
MU   117.89 (-1.14%)
CGC   8.63 (-9.63%)
GE   175.53 (-2.55%)
DIS   122.36 (+1.14%)
AMC   3.72 (-14.29%)
PFE   27.75 (-0.11%)
PYPL   66.99 (+0.63%)
XOM   116.24 (+1.10%)
NASDAQ:RPTX

Repare Therapeutics (RPTX) Stock Price, News & Analysis

$4.71
+0.04 (+0.86%)
(As of 05:22 PM ET)
Today's Range
$4.35
$4.88
50-Day Range
$4.53
$8.41
52-Week Range
$3.08
$13.85
Volume
247,681 shs
Average Volume
153,695 shs
Market Capitalization
$174.27 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$17.33

Repare Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
260.4% Upside
$17.33 Price Target
Short Interest
Healthy
2.31% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
-0.59mentions of Repare Therapeutics in the last 14 days
Based on 9 Articles This Week
Insider Trading
Selling Shares
$36,956 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($2.74) to ($3.08) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.00 out of 5 stars

Medical Sector

509th out of 938 stocks

Pharmaceutical Preparations Industry

241st out of 433 stocks

RPTX stock logo

About Repare Therapeutics Stock (NASDAQ:RPTX)

Repare Therapeutics Inc., a clinical-stage precision oncology company, engages in the discovery and development of therapeutics by using its synthetic lethality approach in Canada and the United States. It uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform, to discover, validate, and build a pipeline of SL-based therapeutics that focuses on genomic instability, including DNA damage repair. The company's lead product candidate is Camonsertib (RP-3500), an oral small molecule inhibitor under Phase ½ development for the treatment of solid tumors with specific DNA damage repair-related genomic alterations. It is also developing Lunresertib (RP-6306), a PKMYT1 Inhibitor, which is under Phase 1 clinical trial for tumors with genetic alterations characterized by CCNE1 amplification; RP-1664, an oral PLK4 inhibitor, under Phase 1 clinical trial designed to harness the synthetic lethal relationship with TRIM37 amplification or overexpression in solid tumors; and RP-3467, a polymerase theta adenosinetriphosphatase (ATPase) inhibitor, a SL target associated with BRCA mutations and other genomic alterations. The company has license and collaboration agreement with Hoffmann-La Roche Inc. and F. Hoffmann-La Roche Ltd; Bristol-Myers Squibb Company; New York University; and Ono Pharmaceutical Co., as well as a clinical study and collaboration agreement with Debiopharm to explore the synthetic lethal combination of PKMYT1 and WEE1 inhibition in cancer. Repare Therapeutics Inc. was incorporated in 2016 and is headquartered in Montréal, Canada.

RPTX Stock Price History

RPTX Stock News Headlines

Grab Your Free Bitcoin Today!
And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.
RPTX Apr 2024 7.500 call
RPTX Jul 2024 7.500 call
Grab Your Free Bitcoin Today!
And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.
Recap: Repare Therapeutics Q4 Earnings
RPTX Mar 2024 7.500 call
Repare Therapeutics Inc (RPTX)
EBS Sep 2024 7.500 put
See More Headlines
Receive RPTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Repare Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/28/2024
Today
3/28/2024
Next Earnings (Estimated)
5/14/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:RPTX
Fax
N/A
Employees
179
Year Founded
2016

Price Target and Rating

Average Stock Price Target
$17.33
High Stock Price Target
$25.00
Low Stock Price Target
$10.00
Potential Upside/Downside
+260.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Net Income
$-93,800,000.00
Net Margins
-183.43%
Pretax Margin
-201.79%

Debt

Sales & Book Value

Annual Sales
$51.13 million
Book Value
$5.03 per share

Miscellaneous

Free Float
30,160,000
Market Cap
$177.97 million
Optionable
Optionable
Beta
0.62

Social Links

The Best High-Yield Dividend Stocks for 2024 Cover

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

  • Mr. Lloyd Mitchell SegalMr. Lloyd Mitchell Segal (Age 60)
    President, CEO & Director
    Comp: $913.39k
  • Dr. Michael Zinda Ph.D. (Age 53)
    Executive VP & Chief Scientific Officer
    Comp: $641.53k
  • Dr. Maria Koehler M.D. (Age 67)
    Ph.D., Executive VP & Chief Medical Officer
    Comp: $682.8k
  • Dr. Daniel Durocher Ph.D.
    Co-Founder
  • Dr. Frank Sicheri Ph.D.
    Co-Founder
  • Dr. Agnel Sfeir Ph.D.
    Co-Founder
  • Mr. Steve Forte (Age 45)
    Executive VP & CFO
    Comp: $608.52k
  • Mr. Daniel Belanger
    Executive Vice President of Human Resource
  • Mr. Cameron Black
    Executive Vice President of Discovery
  • Dr. Kim A. Seth Ph.D.
    Executive VP & Chief Business Officer

RPTX Stock Analysis - Frequently Asked Questions

Should I buy or sell Repare Therapeutics stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Repare Therapeutics in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" RPTX shares.
View RPTX analyst ratings
or view top-rated stocks.

What is Repare Therapeutics' stock price target for 2024?

4 Wall Street analysts have issued 1-year target prices for Repare Therapeutics' stock. Their RPTX share price targets range from $10.00 to $25.00. On average, they predict the company's stock price to reach $17.33 in the next year. This suggests a possible upside of 260.4% from the stock's current price.
View analysts price targets for RPTX
or view top-rated stocks among Wall Street analysts.

How have RPTX shares performed in 2024?

Repare Therapeutics' stock was trading at $7.30 at the beginning of 2024. Since then, RPTX shares have decreased by 34.1% and is now trading at $4.81.
View the best growth stocks for 2024 here
.

When is Repare Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our RPTX earnings forecast
.

How were Repare Therapeutics' earnings last quarter?

Repare Therapeutics Inc. (NASDAQ:RPTX) posted its quarterly earnings data on Wednesday, February, 28th. The company reported ($0.67) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.56) by $0.11. The business had revenue of $13.05 million for the quarter, compared to the consensus estimate of $15.92 million. Repare Therapeutics had a negative trailing twelve-month return on equity of 39.82% and a negative net margin of 183.43%.

What ETF holds Repare Therapeutics' stock?

ARK Genomic Revolution ETF holds 2,713,177 shares of RPTX stock, representing 0.98% of its portfolio.

What other stocks do shareholders of Repare Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Repare Therapeutics investors own include Boeing (BA), Marvell Technology (MRVL), Adobe (ADBE), Albertsons Companies (ACI), Abbott Laboratories (ABT), AES (AES), Autodesk (ADSK) and

When did Repare Therapeutics IPO?

Repare Therapeutics (RPTX) raised $126 million in an initial public offering (IPO) on Friday, June 19th 2020. The company issued 7,400,000 shares at $16.00-$18.00 per share. Morgan Stanley, Goldman Sachs, Cowen and Piper Sandler acted as the underwriters for the IPO.

Who are Repare Therapeutics' major shareholders?

Repare Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional investors include BVF Inc. IL (24.53%), Blue Owl Capital Holdings LP (7.41%), ARK Investment Management LLC (6.70%), GSA Capital Partners LLP (0.34%), Vanguard Group Inc. (0.15%) and Vanguard Group Inc. (0.15%). Insiders that own company stock include Ansbert Gadicke, Bvf Partners L P/Il, David P Bonita, Davis Jerel, John A Mastalerz Jr, Lloyd Mitchell Segal, Michael Zinda, Orbimed Advisors Llc, Steve Forte, Thomas Civik and Todd Foley.
View institutional ownership trends
.

How do I buy shares of Repare Therapeutics?

Shares of RPTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:RPTX) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners